Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Mallinckrodt
Baxter
Johnson and Johnson
Dow

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Metreleptin

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Metreleptin: Patents, clinical trial progress, indications

Metreleptin is an investigational drug.

There have been 22 clinical trials for Metreleptin. The most recent clinical trial was a Phase 2 trial, which was initiated on November 14th 2018.

The most common disease conditions in clinical trials are Lipodystrophy, Body Weight, and Non-alcoholic Fatty Liver Disease. The leading clinical trial sponsors are National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), AstraZeneca, and University of Michigan.

There are fifteen US patents protecting this investigational drug and three hundred and forty international patents.

Recent Clinical Trials for Metreleptin
TitleSponsorPhase
Immunogenicity of Metreleptin in Patients With Generalized LipodystrophyAegerion Pharmaceuticals, Inc.Phase 4
CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial LipodystrophyUniversity of MichiganPhase 2
Expanded Access Metreleptin StudyUniversity of MichiganPhase 2

See all Metreleptin clinical trials

Clinical Trial Summary for Metreleptin

Top disease conditions for Metreleptin
Top clinical trial sponsors for Metreleptin

See all Metreleptin clinical trials

US Patents for Metreleptin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Metreleptin   Start Trial Methods of treating obesity with two different anti-obesity agents Amylin Pharmaceuticals LLC (San Diego, CA) AstraZeneca Pharmaceuticals LP (Wilmington, DE)   Start Trial
Metreleptin   Start Trial FZD8 extracellular domains and FZD8 extracellular domain fusion molecules and treatments using same Five Prime Therepeutics, Inc. (South San Francisco, CA)   Start Trial
Metreleptin   Start Trial Pyrrolidinone derivatives as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders Sanofi (Paris, FR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Johnson and Johnson
Baxter
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.